Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kite Pharma

Gilead Sciences

Priority FDA review for new Gilead HCV combination therapy

Sovaldi/velpatasvir combination could be approved in the US by summer 2016

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Gilead Sciences

Gilead receives FDA approval for PAH combo

Letairis with tadalafil given the nod for pulmonary arterial hypertension

National Institute for Health and Care Excellence NICE logo

NICE gives nod to Gilead’s Zydelig

First class of drug to be recommended for leukaemia

Gilead Sciences

Gilead reports positive data on ‘universal’ hepatitis C regimen

Sets sights on regulatory approval for combination therapy 

- PMLiVE

Gilead and GSK pulmonary hypertension drugs work in tandem

Letairis and Adcirca combined shows clear therapeutic benefit

Roche Basel Switzerland

Roche and AbbVie’s leukaemia drug set for filing by year-end

Blood cancer treatment venetoclax faces a tough market if approved

- PMLiVE

Humira gains EU licence first for Hidradenitis Suppurativa

Thirteenth licence for the drug in Europe

Gilead Sciences

Gilead files Complera follow-up with FDA

HIV therapy could be approved in the US by the end of this year

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links